139 results about "Phospholipase" patented technology

The disclosure encompasses genetically modified plants and methods for improving phosphorus redistribution and use efficiency. The genetically modified plants increase the expression of a nonspecific phospholipase C4 (NPC4) protein, enhancing phosphorus remobilization from old, senescing tissues to young, growing tissues and seeds. The genetic modification improves plant growth, increases seed and oil yield, and alters fatty acid composition. The genetically modified plants demonstrate enhanced phosphorus use efficiency under phosphorus-limited conditions, showing greater growth and yield improvements compared to wild-type plants. Specifically in camelina plants, the genetic modification increases seed yield, elevates oil content, and alters fatty acid composition of the oil under P-limited conditions.

Provided are a marine phospholipase C mutant and a use thereof. Compared with wild-type (WT) enzyme protein, at 40°C and under conditions where enzyme protein activity remains essentially unchanged, the enzyme protein half-life of the constructed mutant can be increased to 3.46 and 9.25 times that of the original enzyme protein, and the residual phosphorus content in degummed oil can be reduced from 551 ppm to 72 ppm, which shows a significant improvement over the final residual phosphorus content of 175 ppm for the blank control and the final residual phosphorus content of 131 ppm for the WT. These results demonstrate that the enzyme has improved thermal stability, enables oil degumming under various conditions, and is suitable for a broader range of industrial applications.

Disclosed is a method for reducing the usage amount of edible fat and oil in a bakery product, the method comprising mixing at least one maltose alpha-amylase and edible fat and oil into dough, and baking same to prepare a bakery product. The usage amount of the edible fat and oil in the dough can be reduced by at least 10 wt % compared with not using the enzyme treatment; and the enzyme may also include cellulase and / or phospholipase. The method does not reduce or substantially reduce the quality of the bakery product, and allows same to have a shelf life of at least 4 days. Also involved is baked fat and oil prepared from the above-mentioned enzyme and edible fat and oil.

The invention relates to a haploid induction method based on a brassica napus phospholipase gene BnaPLA2-a and application of the haploid induction method, the BnaPLA2-a gene in brassica napus is knocked out through a gene editing technology, a mutant material capable of inducing haploid generation is obtained, and the application blank of a phospholipase pathway in dicotyledon haploid induction is filled. Compared with a traditional microspore culture technology, the invention provides a brand-new haploid induction path which is derived from the rape and is used for the rape. The invention provides a brand new technical tool and germplasm resources for genetic breeding of brassica napus. Meanwhile, the invention discloses a gene, a mutant, a creation method and application in breeding.

The invention discloses a phospholipase D mutant with improved thermal stability and a preparation method thereof. The amino acid sequence of the phospholipase D mutant is as shown in SEQ ID NO.4; according to the phospholipase D mutant A426P with improved thermal stability, the mutant is incubated for 30 min at 55 DEG C and 60 DEG C respectively, the residual enzyme activity is 85% and 58% respectively, the activity of wild-type enzyme is only 56% and 7% under the same treatment condition, the thermal stability of the mutant enzyme is remarkably improved, and the phospholipase D mutant A426P can be used as a phospholipase D mutant. The problem that phospholipase D is not ideal in thermal stability in biological catalytic reaction is solved.

The invention discloses a leontopodium alpinum callus extract as well as a preparation method and application thereof, and belongs to the technical field of plant active ingredient extraction. The leontopodium alpinum callus extract is prepared by the following steps: mixing leontopodium alpinum callus freeze-dried powder with a buffer solution, adding cellulase, pectinase and beta-glucanase, uniformly mixing, reacting to obtain primary enzymolysis slurry, adjusting the primary enzymolysis slurry to be neutral, adding phospholipase A2, stirring, reacting to obtain deep enzymatic hydrolysate, filtering, washing, and drying to obtain the leontopodium alpinum callus extract. Transferring into an extraction kettle, adding an entrainer, and extracting to obtain a leontopodium alpinum extract; dissolving soybean phospholipid and cholesterol in ethanol to obtain an organic phase; dispersing the leontopodium alpinum extract in a buffer solution to obtain an active matter water phase; and injecting the organic phase into the active matter water phase, stirring, carrying out reduced pressure distillation, and homogenizing. The preparation method provided by the invention can efficiently and completely obtain the active component, and the nano-liposome formed by phospholipid molecules can effectively improve the stability of the active component.

The invention relates to the technical field of bioengineering, in particular to a preparation process for extracting antihypertensive peptide from euphausia superba. The process comprises the following steps: adding a ferulic acid / arginine double-grafted pullulan compound in a preparation process, and breaking an emulsification interface by utilizing beta-cyclodextrin adsorption and phospholipase A2 cracking to obtain a soluble pretreatment product; meanwhile, short-time round-trip pH pulse is implemented in the incision enzyme hydrolysis process to activate potential enzyme cutting sites, finally, hydrophobic aggregation peptides are removed through weak acid rapid elution, and excision hydrolysis is performed to obtain a target product with the molecular weight of 0.5-3 kDa, so that dynamic induction and antioxidant steady-state dual control of hydrolysis reaction is realized; the generation proportion of short peptides and the ACE inhibition persistence are improved, and the flavor and the storage stability are remarkably improved. The method is controllable in technological process, high in repeatability and suitable for large-scale preparation of the euphausia superba protein functional peptide and development and application of antihypertensive food.

The present disclosure generally relates to a method for foaming and / or stabilizing foam in a milk or milk- based product, wherein a phospholipase is used to promote foam and / or its stabilization by acting on phospholipids and degrading the same and a use of a phospholipase-treated milk or milk-based product for creating milk foam.

The invention provides a lipoprotein sub-component phospholipid detection kit, and belongs to the field of in-vitro diagnostic reagents, and in particular, the lipoprotein sub-component phospholipid detection kit provided by the invention comprises a reaction reagent, the reaction reagent comprises a buffer solution, a surfactant, magnesium chloride, 4-aminoantipyrine, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3, 3, 4-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5- The preservative is prepared from 2, 5-dimethoxyaniline sodium salt, phospholipase D, choline oxidase, peroxidase, ascorbic acid oxidase, a protective agent and a third preservative. The lipoprotein subfraction phospholipid detection kit provided by the invention can be used for determining the content of lipoprotein subfraction phospholipid by using a VAP system, simultaneously realizes simultaneous detection of a plurality of lipoprotein subfraction phospholipid items for the first time, and has the advantages of high precision and high accuracy.

The invention relates to a phospholipase D mutant Lip-Gri / NQ, a plasmid, a recombinant bacterium and application of the phospholipase D mutant Lip-Gri / NQ and belongs to the field of enzyme engineering, the amino acid sequence of the phospholipase D mutant is shown as SEQ ID NO: 1, and the nucleotide sequence of a gene for coding the phospholipase D mutant Lip-Gri / NQ is shown as SEQ ID NO: 2. The invention also provides a recombinant plasmid and an engineering bacterium containing the gene of the recombinant plasmid phospholipase D mutant Lip-Gri / NQ, and application of the phospholipase D mutant Lip-Gri / NQ in catalyzing phospholipids to generate specific-configuration functional lipids including phosphatidylserine. According to the phospholipase D Lip-Gri disclosed by the invention, wild phospholipase D Lip-Gri from Streptomyces griseofuscus is transformed through site-directed mutagenesis, and the enzyme activity of the obtained mutant is remarkably improved and is 11 times that of the wild phospholipase D Lip-Gri.

Engineered phospholipase D mutants are described herein. Also described herein are methods of making engineered phospholipase D mutants. Additionally, methods of using engineered phospholipase D mutants are described.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention relates to nucleic acid aptamers for lipoprotein-associated phospholipase A2 (Lp-PLA2), wherein the nucleic acid aptamer is at least one of B76-2, B76-4, and B76-5, with sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively. The Lp-PLA2 aptamers provided by this invention fill a gap in the field of Lp-PLA2 aptamers and exhibit high affinity and specificity. Three aptamers with good affinity and specificity for Lp-PLA2 have been screened and verified. These aptamers can be formulated into molecular probes or used as detection reagents in methods or kits for detecting Lp-PLA2, improving accuracy. They can also be used to develop novel Lp-PLA2 biosensing methods for molecular identification, showing great application potential in the early warning of cardiovascular disease events.

The invention discloses a method for improving yield of anthocyanin extracted by an enzymic method, according to the method, phospholipase is added and used to act on a cell membrane structure, so that the extraction rate of the anthocyanin and the extraction rate of galactoside in the anthocyanin are obviously improved, and the extraction effect of the anthocyanin is greatly improved through a three-stage enzymolysis system. The total enzymolysis extraction time is within 4 h, and compared with 6-7 h of a traditional enzymatic extraction process, the production period is greatly shortened.

The application discloses application of phospholipase in promoting phosphorus removal in water body, and belongs to the technical field of water treatment. The phospholipase is added to a wetland or a constructed wetland system, the phospholipase catalyzes degradation of organic phosphorus into intermediates, and then shortens the time for conversion of the organic phosphorus into absorbable phosphorus, accelerates the conversion of the phosphorus into the absorbable phosphorus, improves the absorption efficiency of plants on the phosphorus, and thus improves the removal efficiency of the wetland or the constructed wetland system on the phosphorus in the water body.

To provide therapies for subjects suffering from NAFLD.SOLUTION: A double stranded ribonucleic acid (RNAi) agent for inhibiting expression of Patatin-Like Phospholipase Domain Containing 3 is used which comprises a sense strand and an antisense strand. The sense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from a specific nucleotide sequence. The antisense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from another specific nucleotide sequence.SELECTED DRAWING: Figure 1

To obtain a novel phospholipase D against choline-type plasmalogen.SOLUTION: Prepared is a phospholipase D comprising any of the described polypeptides: (1-1) a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1; (1-2) a polypeptide having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 1, and having a hydrolytic activity to a phosphate ester bond in a choline-type plasmalogen molecule in which oleic acid is ester-bonded to the sn-2 position of a glycerol skeleton; and (1-3) a polypeptide in which one or several amino acids are added, substituted, deleted and / or inserted in the amino acid sequence set forth in SEQ ID NO: 1, and having a hydrolytic activity to a phosphate ester bond in a choline-type plasmalogen molecule.SELECTED DRAWING: Figure 3

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

The present application relates to the technical field of wastewater treatment of gold hydrometallurgy process, and particularly discloses a biological treatment method of gold smelting wastewater.A biological treatment method of gold smelting wastewater, comprising acid-base adjustment, sulfidation reaction, first flocculation and precipitation, biological treatment, second flocculation and precipitation, and monitoring and discharge; wherein the immobilized biochar used in the biological treatment is prepared by mixing activated sludge after banana stem, cassava residue and kelp are selected as the source of biochar and then the nutrients such as urea, starch phosphate sodium, phospholipase C, cobalt chloride, zinc chloride and magnesium chloride are attached to the biochar.The present application has the effect of improving the efficiency of biological treatment of acidic wastewater.

The application provides a lipoprotein phospholipase A2 determination kit for latex immunoturbidimetry, which contains reagent R1 and reagent R2; the reagent R1 comprises the following components: buffer, inorganic salt, anti-interference additive, surfactant and Proclin 300; the reagent R2 comprises the following components: buffer, lipoprotein phospholipase A2 antibody coated latex microspheres, stabilizer, surfactant and Proclin 300. The kit is a liquid kit with strong stability, high accuracy, wide linear range and strong anti-HOOK capability.

The invention discloses an application of glycosylated phosphatidylinositol specific phospholipase D1 (GPLD1) as a sperm-egg recognition and / or binding regulation molecule.

The invention relates to the technical field of pharmaceutical preparations, in particular to an EPA phospholipid soft capsule composition and a preparation method thereof.The composition comprises EPA phospholipid and an enteric soft capsule shell, the EPA phospholipid is prepared from EPA ethyl ester and a reaction substrate under the action of immobilized phospholipase, and the enteric soft capsule shell comprises an enteric material, a plasticizer and purified water. According to the EPA phospholipid enteric-coated soft capsule provided by the invention, EPA ethyl ester is phosphatidylated, and EPA phospholipid is prepared into the enteric-coated soft capsule, so that stable retention of a medicine in the stomach can be reduced, accurate dissolution of the medicine in the small intestine is realized, the problems of peculiar smell and degradation caused by release of EPA ethyl ester in the stomach are effectively avoided, and the EPA phospholipid enteric-coated soft capsule has the characteristic of pH-enzyme dual response.

A mutated phospholipase C enzyme, comprising an amino acid sequence wherein at least one amino acids is substituted in the position selected from the group consisting of 120, 85, 88, 106, 121, 188, 189, 230, 53, 82, 178 and 194 of the amino acid sequence of SEQ ID No. 1, or an amino acid sequence with at least 80% identical of SEQ ID No. 1.

RNAi agents, compositions, and methods for reducing patatin-like phospholipase domain-containing protein-3 (PNPLA3) levels and treating liver disease, such as NAFLD, are provided.SOLUTION: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting the expression of PNPLA3 genes. Pharmaceutical compositions comprising the PNPLA3RNAi drugs and methods of use thereof are also disclosed. The disclosed PNPLA3RNAi drugs may be conjugated to targeting ligands to facilitate delivery to cells, including hepatocytes. Delivery of the PNPLA3RNAi agent in vivo provides for inhibition of expression of the PNPLA3 gene. The RNAi agents can be used in methods of treating PNPLA3 associated diseases and disorders, including alcoholic or non-alcoholic liver disease, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic fat liver disease (NASH), liver fibrosis, and cirrhosis.SELECTED DRAWING: None

Compositions and methods are provided that are useful for reducing expression of the patatin-like phospholipase domain-containing 3 (PNPLA3) gene and treating PNPLA3-related diseases and conditions. Provided are PNPLA3 dsRNA agents, PNPLA3 antisense polynucleotide agents, compositions comprising PNPLA3 dsRNA agents, and compositions comprising PNPLA3 antisense polynucleotide agents that can be used to reduce PNPLA3 expression in cells and subjects.

This invention discloses a phospholipase D and its application in the preparation of ω-3 PUFAs-PA, belonging to the field of functional enzyme technology. The amino acid sequence of the phospholipase D is shown in SEQ ID NO. 9. The application of phospholipase D in the preparation of ω-3 PUFAs-PA is also disclosed. This invention also discloses a recombinant engineered bacterium expressing OUC-nPLD. The phospholipase D of this invention—OUC-nPLD—is a recombinant enzyme obtained by functional domain recombination based on the Non-HKD phospholipase D of *Streptomyces aquamarine*, and its PLD hydrolytic activity is 221.73 U / mg. This invention constructs a recombinant engineered bacterium expressing OUC-nPLD. The OUC-nPLD of this invention can be used for the efficient preparation of ω-3 PUFAs-PA, which is of great significance for the large-scale production of ω-3 PUFAs-PA.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The invention discloses a method for producing phosphatidylserine through enzyme catalysis, and belongs to the technical field of biology, and the method specifically comprises the following steps: in a reaction system of a [BMIM] [BF4] aqueous solution, taking natural phospholipid containing phosphatidylcholine and cephalin as a raw material, adding L-serine, calcium salt and phospholipase D, and carrying out a trans-acylation reaction. By introducing cephalin (4%-10%, preferably 6%-8%) and sphingomyelin (5%-10%) in a specific proportion and combining with a [BMIM] [BF4] ionic liquid system, high efficiency and high purity (the purity gt, 79.6% and the yield gt, 76.4%) of PS production are realized, and the problem that the yield and the purity cannot be considered at the same time in the traditional process is thoroughly solved.

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and to methods of preventing and treating an PNPLA3-associated disorder, e.g., Nonalcoholic Fatty Liver Disease (NAFLD).

The present invention addresses the problem of imparting a mellow feeling to a plant-based oil-in-water emulsion. A plant-based oil-in-water emulsion which is characterized by satisfying all of the following conditions (a) to (c). (a) comprises a lipid. And (b) as a plant raw material, a plant raw material containing phospholipids treated with phospholipase. And (c) the content of the phospholipid derived from the plant raw material is 0.003% by weight or more in the oil-in-water emulsion.